These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 19400225)

  • 21. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.
    Law M; Cardoso RM; Wilson IA; Burton DR
    J Virol; 2007 Apr; 81(8):4272-85. PubMed ID: 17267498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV.
    Van Regenmortel MHV
    Vaccine; 2017 Apr; 35(16):1985-1986. PubMed ID: 28320589
    [No Abstract]   [Full Text] [Related]  

  • 23. Rational dissection of binding surfaces for mimicking of discontinuous antigenic sites.
    Villén J; Rodríguez-Mias RA; Núñez JI; Giralt E; Sobrino F; Andreu D
    Chem Biol; 2006 Aug; 13(8):815-23. PubMed ID: 16931331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate.
    Pfeiffer B; Peduzzi E; Moehle K; Zurbriggen R; Glück R; Pluschke G; Robinson JA
    Angew Chem Int Ed Engl; 2003 May; 42(21):2368-71. PubMed ID: 12783498
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV vaccines. Magic of the occult?
    Montefiori D; Moore JP
    Science; 1999 Jan; 283(5400):336-7. PubMed ID: 9925493
    [No Abstract]   [Full Text] [Related]  

  • 26. Towards a multi-site synthetic vaccine to foot-and-mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals.
    Villén J; de Oliveira E; Núñez JI; Molina N; Sobrino F; Andreu D
    Vaccine; 2004 Sep; 22(27-28):3523-9. PubMed ID: 15315831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Full-length HIV-1 Tat protein necessary for a vaccine.
    Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trick and treat: toward peptide mimic vaccines.
    Shikhman AR; Cunningham MW
    Nat Biotechnol; 1997 Jun; 15(6):512-3. PubMed ID: 9181569
    [No Abstract]   [Full Text] [Related]  

  • 29. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.
    Wahome N; Pfeiffer T; Ambiel I; Yang Y; Keppler OT; Bosch V; Burkhard P
    Chem Biol Drug Des; 2012 Sep; 80(3):349-57. PubMed ID: 22650354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995.
    Berzofsky JA; Berkower IJ
    AIDS; 1995; 9 Suppl A():S143-57. PubMed ID: 8819581
    [No Abstract]   [Full Text] [Related]  

  • 31. Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design.
    Hu D; Bowder D; Wei W; Thompson J; Wilson MA; Xiang SH
    Vaccine; 2017 May; 35(23):3067-3075. PubMed ID: 28461065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.
    Wyatt LS; Earl PL; Liu JY; Smith JM; Montefiori DC; Robinson HL; Moss B
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):645-53. PubMed ID: 15242542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Liposomes to Shape Epitope Structure and Modulate Immunogenic Responses of Peptide Vaccines Against HIV MPER.
    Apellániz B; Nieva JL
    Adv Protein Chem Struct Biol; 2015; 99():15-54. PubMed ID: 26067815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to HIV-1: aiming at the right target.
    Eggink D; Melchers M; Sanders RW
    Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.
    Luo M; Capina R; Daniuk C; Tuff J; Peters H; Kimani M; Wachihi C; Kimani J; Ball TB; Plummer FA
    Vaccine; 2013 Jun; 31(29):3000-8. PubMed ID: 23664989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
    McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
    J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.